Clinical effect of Irbesartan combined with Xinkeshu in the treatment of patients with abdominal obesity complicated with essential hypertension and hyperlipidemia
LIU Juan-feng WANG Li-jun WANG Ping
Department of Cardiology, the First People′s Hospital of Jingdezhen City, Jiangxi Province, Jingdezhen 333000, China
Abstract：Objective To observe the clinical effect of Irbesartan combined with Xinkeshu in the treatment of patients with abdominal obesity complicated with essential hypertension and hyperlipidemia.Methods One hundred patients with abdominal obesity complicated with essential hypertension and hyperlipidemia who were treated in our hospital from June 2017 to September 2018 were selected as subjects.According to the different treatment methods, they were divided into experimental group and control group, each group with 50 cases.Patients in the experimental group were treated with Irbesartan combined with Xinkeshu, while patients in the control group were treated with Irbesartan alone.The therapeutic effect, blood pressure and blood lipid before and after treatment were compared between the two groups.Results The total effective rate in the control group was 90.0%, and the total effective rate in the experimental group was 92.0%.There was no significant difference in the total effective rate between the two groups (P＞0.05).After treatment, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the two groups were lower than before, and the differences were statistically significant (P＜0.05).There were no significant differences in SBP and DBP between the two groups after treatment (P＞0.05).After treatment, the triglyceride (TG), total cholesterol (TC) and lowdensity lipoprotein cholesterol (LDL-C) in the two groups were all lower than before treatment, with statistically significant differences (P＜0.05).The TG, TC and LDL-C in the experimental group were lower than those in the control group after treatment, with statistically significant differences (P＜0.05).Conclusion Xinkeshu could not effectively reduce the blood pressure of patients in terms of treatment, but compared with Irbesartan alone, Xinkeshu could improve the blood lipid level in patients.The combined use of Xinkeshu and Irbesartan in the treatment of patients with abdominal obesity complicated with essential hypertension and hyperlipidemia, can achieve a better effect, which is worthy of being popularized and applied in clinical treatment.
刘鹃锋; 王丽君; 王平. 厄贝沙坦联合心可舒治疗腹型肥胖合并原发性高血压高、血脂患者的临床效果[J]. 中国当代医药, 2020, 27(3): 84-87.
LIU Juan-feng; WANG Li-jun; WANG Ping. Clinical effect of Irbesartan combined with Xinkeshu in the treatment of patients with abdominal obesity complicated with essential hypertension and hyperlipidemia. 中国当代医药, 2020, 27(3): 84-87.
京公网安备 11010502046607号